The prionoid propagation mechanism represents a unifying framework for understanding disease progression across multiple neurodegenerative proteinopathies. This pathway encompasses the template-directed misfolding and cell-to-cell transmission of pathological protein aggregates in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's disease (HD). Unlike classical prion diseases, these disorders are not infectious between individuals but share the fundamental property that misfolded proteins can "infect" neighboring cells and spread pathology through anatomically connected networks.
The central principle underlying all prionoid propagation is template-directed misfolding (also termed "seeded aggregation" or "nucleated polymerization"). This process involves the templated conversion of normal, correctly folded proteins into pathological conformations by interaction with pre-existing misfolded aggregates[1][2].
The template-directed misfolding mechanism operates through several key steps:
This mechanism fundamentally distinguishes prionoid diseases from conditions where protein accumulation occurs solely through increased production or decreased clearance[3].
All neurodegenerative disease-associated proteins that exhibit prionoid propagation share several structural and biochemical properties:
The recognition that multiple neurodegenerative diseases share this propagation mechanism has revolutionized our understanding of disease progression and opened new therapeutic avenues targeting the common final pathway of protein misfolding and spread[4].
The term "strain" refers to distinct conformational variants of the same protein that differ in their biological properties despite having identical amino acid sequences. This concept was first established in prion diseases but has since been extended to include tau, alpha-synuclein, TDP-43, and huntingtin aggregates[5][6].
Strain diversity arises from the ability of proteins to adopt multiple distinct amyloid folds. Each strain represents a different "self-propagating" conformation that can template its own conversion of normal protein. This has profound implications for:
Tau protein exhibits remarkable strain diversity that correlates with different clinical phenotypes[7][8]:
| Strain | Isoform Composition | Associated Diseases | Morphology |
|---|---|---|---|
| AD-type | 3R + 4R (mixed) | Alzheimer's disease | Paired helical filaments |
| CBD-type | 4R predominant | Corticobasal degeneration | Straight filaments |
| PSP-type | 4R predominant | Progressive supranuclear palsy | Straight filaments |
| AGD-type | 4R predominant | Argyrophilic grain disease | Short filaments |
| Pick-type | 3R predominant | Pick's disease | Round filaments |
Cryo-electron microscopy has revealed distinct atomic structures of tau filaments from different diseases, providing a structural basis for strain classification and explaining the phenotypic diversity of tauopathies[7:1].
Alpha-synuclein forms multiple distinct aggregate strains that correspond to different clinical entities[9][10]:
Different alpha-synuclein strains show distinct:
These strain differences help explain why alpha-synuclein pathology can present with such varied clinical phenotypes, from classic PD to dementia with Lewy bodies to MSA.
TDP-43 protein aggregates in ALS and FTD also exhibit strain-like properties[@porta2018]:
The existence of distinct TDP-43 strains helps explain the clinical overlap and phenotypic diversity within the ALS-FTD spectrum.
Huntingtin protein (HTT) with expanded polyglutamine repeats forms aggregating species that also show strain diversity:
Extracellular vesicles, particularly exosomes, represent a major pathway for intercellular transfer of pathological proteins[11][12]:
Mechanism:
Disease-specific examples:
Exosomes provide a protected environment for protein seeds, shielding them from extracellular proteases and facilitating long-distance propagation[13].
Direct cell-to-cell connections called tunneling nanotubes (TNTs) provide another route for prionoid propagation[14][15]:
Characteristics:
Evidence in neurodegeneration:
Damaged lysosomes can release their contents through lysosomal exocytosis, providing another release pathway[16]:
Some pathological proteins can directly translocate across cell membranes:
Tau pathology follows a characteristic trans-synaptic spreading pattern[17][18]:
The trans-synaptic spread of tau follows functional brain networks, explaining the predictable progression of pathology observed in AD[18:1].
Alpha-synuclein propagation follows both retrograde and anterograde pathways[19][20]:
Retrograde spread (from axon terminal to cell body):
Anterograde spread (from cell body to terminal):
All prionoid proteins follow brain connectivity patterns:
This network-based spread model provides a mechanistic explanation for the characteristic anatomical patterns of neurodegeneration observed in each disease.
Multiple receptors mediate the internalization of pathological proteins[21][22]:
Heparan Sulfate Proteoglycans (HSPGs):
LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1):
Fc-gamma Receptors:
Non-specific pinocytosis also contributes to aggregate uptake:
In some cases, proteins can directly fuse with the plasma membrane:
When multiple protein strains are present, they can compete for the normal protein substrate[23]:
Different proteins can co-aggregate, creating mixed pathology[24]:
One protein aggregate can template the misfolding of a different protein:
Small molecules that prevent protein aggregation represent a key therapeutic approach[25][26]:
Mechanisms:
Examples:
Immunotherapy targeting extracellular pathological proteins is actively being developed[27][28]:
Passive Immunization:
Active Immunization:
Mechanisms of Action:
Genetic interventions offer potential for disease modification[28:1]:
Given the complexity of prionoid propagation, combination approaches are likely to be most effective:
Prusiner SB. "Biology and genetics of prions causing neurodegeneration". Nature Reviews Neuroscience. 2013. ↩︎
Frost B, Diamond MI. "Prion-based diseases: a user guide to the templated misfolding basis of neurodegeneration". Nature Reviews Neuroscience. 2009. ↩︎
Jucker M, Walker LC. "Self-propagation of protein aggregation as a default mechanism in neurodegenerative disease". Nature Neuroscience. 2013. ↩︎
Goedert M. "Neurodegeneration: the misfolded protein is the prion". Nature Reviews Neurology. 2015. ↩︎
Sanders DW, et al. "Distinct tau prion strains propagate in cells and mouse models and produce different patterns of neurodegeneration". Journal of Neuroscience. 2014. ↩︎
Schubert E, et al. "Tau strain variation defines disease progression". Acta Neuropathologica. 2018. ↩︎
Fitzpatrick AWP, et al. "Cryo-EM structures of tau filaments from Alzheimer disease brain". Nature. 2017. ↩︎ ↩︎
Goedert M, et al. "Cryo-EM structures of tau filaments from Alzheimer disease brain". Nature. 2017. ↩︎
Guo JL, et al. "Distinct alpha-synuclein strains: implications for neurodegeneration and disease". Cell. 2013. ↩︎
Aulic S, et al. "Alpha-synuclein strains: the missing link between cellular pathology and disease". Cell and Tissue Research. 2018. ↩︎
Wang Y, et al. "Exosomes in tau propagation". Molecular Neurobiology. 2017. ↩︎ ↩︎
Stojkovska I, et al. "Exosomes in alpha-synuclein propagation". Movement Disorders. 2018. ↩︎ ↩︎
Pegtel DM, et al. "Extracellular vesicles: the next generation of biomarkers". Journal of Extracellular Vesicles. 2014. ↩︎
Costanzo M, et al. "Tunneling nanotubes as a novel pathway for cell-to-cell spread of tau". Journal of Cell Science. 2019. ↩︎ ↩︎
Abounit S, et al. "Tunneling nanotubes: a novel mechanism of alpha-synuclein transmission". Neurobiology of Disease. 2015. ↩︎ ↩︎
Martinez F, et al. "Lysosomal exocytosis in protein propagation". Autophagy. 2019. ↩︎
Auer RN. "Transsynaptic neurodegeneration in Alzheimer disease: an infectious versus native mechanism". Alzheimer's & Dementia. 2015. ↩︎
Calafate S, et al. "Synaptic activity and trans-synaptic spread of tau". Acta Neuropathologica. 2015. ↩︎ ↩︎
Recasens A, et al. "Inside-out transplantations of alpha-synuclein-expressing grafted neurons in a rat model of Parkinson's disease". Acta Neuropathologica. 2014. ↩︎
Valdinocci D, et al. "Potential routes for propagation of synucleinopathy". Frontiers in Neurology. 2017. ↩︎
Holmes BB, et al. "Heparan sulfate proteoglycans mediate internalization of proteopathic tau seeds by neurons". Acta Neuropathologica. 2013. ↩︎ ↩︎
Benarroch L, et al. "Tau receptors on neurons: relevance to neurodegeneration". Neurology. 2018. ↩︎
Roperto L, et al. "Strain competition in prionoid protein aggregation". Prion. 2019. ↩︎
Bertelsen M, et al. "Co-aggregation of protein aggregates in neurodegenerative disease". Brain. 2021. ↩︎
Soto C, et al. "Targeting protein misfolding in neurodegenerative diseases". Nature Reviews Drug Discovery. 2020. ↩︎
Javed H, et al. "Anti-aggregation therapy for neurodegenerative diseases". Expert Opinion on Therapeutic Targets. 2019. ↩︎
Bae EJ, et al. "Anti-prion strategies for neurodegenerative disease". Experimental Neurobiology. 2019. ↩︎
Scialo C, et al. "Targeting propagation in neurodegenerative disease". Trends in Cell Biology. 2020. ↩︎ ↩︎